CCL2 and glioblastoma: Particularly important, in the experiment of the allogeneic intracranial orthotopic GBM model, deguelin showed the ability to inhibit tumor growth and inhibit GBM angiogenesis by inhibiting the CCL2/NF-κB pathway in vivo.